5 Crescent Drive
GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.
GSK's mission is to improve the quality of human life by enabling people to do more, feel better and live longer.
Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products.
The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders.
Based on 2000 Preliminary Annual Results, GSK had sales of £18.1 billion ($27.5 billion) and profit before tax of £5 billion ($8.1 billion). Pharmaceutical sales accounted for £15.4 billion ($23.5 billion), 85 per cent of the total.
GSK had four products with sales of over $1 billion and a total of 16 products with sales in excess of $500 million.
GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Almost 40,000 employees work at 108 manufacturing sites in 41 countries and over 16,000 are in R&D.
2828 articles with GlaxoSmithKline
Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.
Jack Bailey, head of the company’s U.S. pharmaceuticals business is stepping down at the end of the year.
Kadans Science Partner Invests in Stevenage UK Enabling Future Growth of the Research & Development Base
Kadans expands its presence in the United Kingdom by adding its second research hub in the country to its Pan-European science park portfolio.
8/6/2019The vaccines are for Ebola Zaire, Ebola Sudan and the Marburg virus. Currently no licensed vaccines against these three viruses are available. All three diseases have a death rate of about 50%.
Pfizer Announces Closing of Joint Venture With GlaxoSmithKline to Create a Premier Global Consumer Healthcare Company
Combined brand portfolio forms the world's largest over-the-counter business with leadership positions in Pain Relief, Respiratory and Vitamins, Minerals and Supplements, and Therapeutic Oral Health
De-risk proposals and ensure internal buy-in to guarantee approval and commercial success of digital business plans. [29-July-2019] PHILADELPHIA , July 29, 2019 /PRNewswire/ -- The 13th Digital Pharma East returns to the Pennsylvania Convention Center on September 17–20 . Join us — and more than 1,000 attendees — for four days of interactive learning and ne
7/22/2019Here's a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
It's no secret that artificial intelligence and machine learning play key roles in drug development. This week, multiple companies have advanced their AI programming.
7/15/2019According to reports, Novartis veteran Jonathan Symonds is likely to be named the next chairman of the board.
7/15/2019It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
ViiV Healthcare Announces Phase III Study Meets Primary Endpoint, Demonstrating the Ability to Control HIV-1 With the 2-drug Regimen Dovato in Virally Suppressed Patients Switching From a TAF-containing, 3-drug Regimen
Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019)
The two-drug combination of Dovato provided similar long-term viral suppression to common three-drug regimens.
MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019
MorphoSys AG announced that its licensing partner GSK reported in a press release earlier the start of a phase 3 clinical development program with otilimab in rheumatoid arthritis.
Despite Political Rhetoric, Some Drug Prices Jumped on July 1, Including Medicines on Shortage Lists
7/2/2019The beginning of July is when many companies increase the price on prescription medications in the U.S. This year's price increases are higher than the same period last year.
SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma
SpringWorks Therapeutics, Inc. announced that the company has entered into a clinical trial collaboration agreement with GlaxoSmithKline to evaluate SpringWorks Therapeutics’ investigational gamma secretase inhibitor, nirogacestat, in combination with GlaxoSmithKline’s investigational anti-B-cell maturation antigen antibody-drug conjugate, belantamab mafodotin, in patients with relapsed or refractory multiple myeloma.
According to a report, GSK has bundled the products into three separate packets in order to attract regional buyers.
Parasitic Diseases Therapeutics Market Worth USD 1.79 Billion, at 5% CAGR During 2019-2023 | Technavio
According to Technavio Research Report "Parasitic Diseases Therapeutics Market by type and geographic regions is witnessed to grow USD 1.79 billion, at a CAGR of 5% from 2019 to 2023”.
The Laboratory for Genomics Research will be funded by GSK up to $67 million over the five-year period and will include space for 24 full-time university employees and up to 14 full-time GSK staffers.
A Phase III trial compared Sanofi’s Soliqua/Suliqua to other GLP-1 receptor agonists (GLP-1 RA), with Soliqua showing a superior decrease of average blood sugar level (HbA1c) after 26 weeks.
First anti-IL5 biologic to give healthcare professionals choice of how and where their patients receive treatment